Insulin degludec: a new basal insulin analogue with an ultra-long duration of action. Safety and efficacy in Russian patients with diabetes
Aims. Insulin degludec (IDeg) is a novel insulin analogue that, following subcutaneous injection, forms soluble multihexamers, resulting in an ultra-long duration of action, which is two-fold longer than that of insulin glargine (IGlar). We present data from Russian cohorts of two multinational, ope...
Saved in:
Main Authors: | Marina Vladimirovna Shestakova, Michail Vladimirovich Antciferov, Alexander Yur'evich Mayorov, Luydmila Alexandrovna Ruyatkina, Ludmila Alexandrovna Suplotova, Sergey Anatol'evich Dogadin, Nikolay Borisovich Lebedev, Yana Gennadievna Alekseeva |
---|---|
Format: | article |
Language: | EN RU |
Published: |
Endocrinology Research Centre
2015
|
Subjects: | |
Online Access: | https://doaj.org/article/addf81b97bd5452b82b135e445ce89a8 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The first and only combination of basal and prandial insulin analogs degludec and aspart: the position of Russian endocrinologists
by: M. V. Shestakova, et al.
Published: (2021) -
Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice
by: Lyudmila Alexandrovna Suplotova, et al.
Published: (2015) -
Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
by: Ivan Ivanovich Dedov, et al.
Published: (2014) -
Modern approach to the evaluation of the pharmacokinetics and pharmacodynamics of biosimilar recombinant human insulin and insulin analogues in I phase clinical study
by: Irina A. Proskurina, et al.
Published: (2016) -
Overcoming marked insulin resistance in a patient with type 2 diabetes mellitus by means of insulin pumptherapy
by: Ekaterina Viktorovna Artemova, et al.
Published: (2012)